Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lymphocyte transformation test follow-up for hypersensitivity after GLPG3067 combinations
NL-OMON45940Not yet recruiting
- Sponsor
- Galapagos NV
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of navocaftor, galicaftor and GLPG2737 in cystic fibrosis (CF) (2 arms), sponsored by Galapagos NV. Primary endpoint: Lymphocyte transformation test assessment. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
navocaftorgalicaftorGLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON45940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45940.